Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesTherapeutic Drug AssaysCPT cpt-80376-drug-testing-panel-4-to-6-substances
    Ask Trek AI about this page

    CPT 80376: Definitive Drug Panel (4–6 Drugs)

    CPT code 80376 describes a clinical laboratory test in which the lab analyst measures the presence or amount of four to six definitive drugs in a patient specimen; this is a qualitative/quantitative multi-drug toxicology panel typically performed as a laboratory diagnostic service on blood or urine specimens in a clinical laboratory or hospital laboratory setting.

    For related coverage guidance, see recent payer policy updates: Bendamustine Products Coverage Criteria, T-Cell Lymphoma Agents: Beleodaq, Istodax, Lymphir, Poteligeo, and Romidepsin, Brentuximab Vedotin (Adcetris®) Coverage Criteria.

    Customize your policy alerts

    Sign up for cpt 80376 policy alerts

    Get alerted when payer policies referencing 80376 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 6

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A community hospital laboratory receives a urine specimen from the emergency department for drug testing after a patient presents with altered mental status and suspected acute intoxication. The laboratory performs definitive toxicology testing to quantify specific drugs and metabolites using mass spectrometry. The service reported is 80376, used when the lab measures the presence or amount of four to six definitive drugs in the specimen. Typical workflow: specimen accessioning and chain-of-custody verification, specimen preparation, analysis by LC-MS/MS or GC-MS, result review by a laboratory scientist, and final reporting to the ordering clinician. Typical site of service is an outpatient or hospital clinical laboratory with specialized toxicology instrumentation. A realistic patient scenario: a 34-year-old found unresponsive at home; emergency clinicians order comprehensive toxicology confirmation to identify multiple suspected substances; the lab runs 80376 to detect and quantify four to six target drugs to guide acute management and disposition.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    80377Drug confirmation; more than six drug classes, each specimen (e.g., definitive testing for larger panels)Performed when a larger definitive panel beyond four to six drugs is required; often used when initial 80376 is insufficient.
    80378Drug confirmation; alternate methodology or additional confirmatory analytes not covered by 80376/80377Used for specialized confirmations or additional analytes requiring separate methods.
    80305Drug assay, qualitative, e.g., immunoassay, each procedureOften performed prior to 80376 as a screening test; positive screens are followed by definitive testing reported under 80376.
    80101Drug test(s), presumptive, any number, non-quantitative, multiple drug classes by high complexity method (e.g., presumptive LC-MS)May be used in facilities that perform presumptive high-complexity testing prior to or instead of definitive confirmation.
    G0480Drug screen, definitive, multiple drug classes, each specimen requiring chromatography/mass spectrometryAlternate HCPCS code used by some payers for definitive drug testing services that correspond clinically to 80376 when billed under different payer rules.

    Related Modifiers

    5 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    56Modifier ‑56 indicates the reporting provider furnished only the preoperative management for a surgical procedure and did not perform the intraoperative or postoperative care. It is used in…- Use Modifier -56 when a provider performs only the preoperative management in a split‑care situation (one physician manages preop care while a different physician performs the intraoperative…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207Q00000X
    207RP1001X
    363L00000X
    3336C0003X
    1835I0206X
    2472D0500X
    163WX1500X
    2251N0400X

    Related Payer Policy Updates

    Specialty: Hematology/Oncology1 / 2

    10 rows

    PolicyPayerEffective Date
    Bendamustine Products Coverage Criteriablue cross blue shield - tennessee2027-01-30
    T-Cell Lymphoma Agents: Beleodaq, Istodax, Lymphir, Poteligeo, and RomidepsinMass General Brigham Health Plan2027-01-04
    Brentuximab Vedotin (Adcetris®) Coverage Criteriablue cross blue shield - tennessee2026-12-31
    Pemetrexed Coverageblue cross blue shield - tennessee2026-12-31
    Tumor Treatment Fields - Medical PolicyHealth-New-England2026-12-01
    Extracorporeal PhotopheresisCigna2026-11-15
    VonvendiCigna2026-11-15
    Hematology - AphexdaCigna2026-11-15
    Extracorporeal PhotopheresisCigna2026-11-15
    Yartemlea (narsoplimab-wuug) Coverage for TA-TMANeighborhood Health Plan of Rhode Island2026-11-01

    Related Codes

    CPT-80143-ACETAMINOPHEN-QUANTITATIVE-SERUM-ASSAY

    CPT 80143: Acetaminophen Quantitative Assay

    CPT-80145-ADALIMUMAB-LEVEL-ASSAY-THERAPEUTIC-DRUG-MONITORING

    CPT 80145: Adalimumab Quantitative Drug Level Assay

    CPT-80150-AMIKACIN-QUANTITATIVE-ASSAY-THERAPEUTIC-DRUG-MONITORING

    CPT 80150: Amikacin Quantitative Serum Level

    CPT-80151-AMIODARONE-QUANTITATIVE-SERUM-ASSAY

    CPT 80151: Amiodarone Quantitative Drug Level Assay

    CPT-80155-CAFFEINE-LEVEL-TESTING

    CPT 80155: Caffeine Level Quantification

    CPT-80156-CARBAMAZEPINE-TOTAL-LEVEL-LAB-ASSAY

    CPT 80156: Carbamazepine Total Level (Serum)

    CPT-80157-FREE-CARBAMAZEPINE-ASSAY

    CPT 80157: Free Carbamazepine Quantitative Assay

    CPT-80158-CYCLOSPORINE-QUANTITATIVE-ASSAY-LAB

    CPT 80158: Cyclosporine Quantitation, Laboratory

    CPT-80159-CLOZAPINE-LEVEL-ASSAY-THERAPEUTIC-DRUG-MONITORING

    CPT 80159: Clozapine Level Measurement

    CPT-80161-CARBAMAZEPINE-EPOXIDE-QUANTITATIVE-ASSAY

    CPT 80161: Carbamazepine 10,11-Epoxide Level, Quantitative

    Showing 1–10 of 87

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.